Submit Feedback
Learn more about Merck & Co.'s Revenue by Segment and Revenue by Region.
Check out competitors to Merck & Co. in a side-by-side comparison.
Explore additional financial metrics for Merck & Co..
| 2015 | 39498000000.00 |
|---|---|
| 2016 | 39807000000.00 |
| 2017 | 40122000000.00 |
| 2018 | 42294000000.00 |
| 2019 | 39121000000.00 |
| 2020 | 41518000000.00 |
| 2021 | 48704000000.00 |
| 2022 | 59283000000.00 |
| 2023 | 60115000000.00 |
| 2024 | 64168000000.00 |
| 2025 | 65011000000.00 |
| Mar 2016 | 9312000000.00 |
|---|---|
| Jun 2016 | 9844000000.00 |
| Sep 2016 | 10536000000.00 |
| Dec 2016 | 10115000000.00 |
| Mar 2017 | 9434000000.00 |
| Jun 2017 | 9930000000.00 |
| Sep 2017 | 10325000000.00 |
| Dec 2017 | 10433000000.00 |
| Mar 2018 | 10037000000.00 |
| Jun 2018 | 10465000000.00 |
| Sep 2018 | 10794000000.00 |
| Dec 2018 | 10998000000.00 |
| Mar 2019 | 10816000000.00 |
| Jun 2019 | 11760000000.00 |
| Sep 2019 | 12397000000.00 |
| Dec 2019 | 11868000000.00 |
| Mar 2020 | 12057000000.00 |
| Jun 2020 | 9353000000.00 |
| Sep 2020 | 10929000000.00 |
| Dec 2020 | 12515000000.00 |
| Mar 2021 | 10627000000.00 |
| Jun 2021 | 11402000000.00 |
| Sep 2021 | 13154000000.00 |
| Dec 2021 | 13521000000.00 |
| Mar 2022 | 15901000000.00 |
| Jun 2022 | 14593000000.00 |
| Sep 2022 | 14959000000.00 |
| Dec 2022 | 13830000000.00 |
| Mar 2023 | 14487000000.00 |
| Jun 2023 | 15035000000.00 |
| Sep 2023 | 15962000000.00 |
| Dec 2023 | 14630000000.00 |
| Mar 2024 | 15775000000.00 |
| Jun 2024 | 16112000000.00 |
| Sep 2024 | 16657000000.00 |
| Dec 2024 | 15624000000.00 |
| Mar 2025 | 15529000000.00 |
| Jun 2025 | 15806000000.00 |
| Sep 2025 | 17276000000.00 |
| Dec 2025 | 16400000000.00 |
| Mar 2026 | 16286000000.00 |
| Jun 2026 | 16607000000.00 |
Merck & Co.'s annual revenue was $65.01 B in fiscal year 2025.
Merck & Co.'s quarterly revenue was $15.53 B(Q1: Mar 2025), $15.81 B(Q2: Jun 2025), $17.28 B(Q3: Sep 2025), $16.40 B(Q4: Dec 2025) in fiscal year 2025.
Merck & Co.'s annual revenue was $64.17 B in fiscal year 2024.
Merck & Co.'s quarterly revenue was $15.78 B(Q1: Mar 2024), $16.11 B(Q2: Jun 2024), $16.66 B(Q3: Sep 2024), $15.62 B(Q4: Dec 2024) in fiscal year 2024.
Merck & Co.'s annual revenue was $60.12 B in fiscal year 2023.
Merck & Co.'s quarterly revenue was $14.49 B(Q1: Mar 2023), $15.04 B(Q2: Jun 2023), $15.96 B(Q3: Sep 2023), $14.63 B(Q4: Dec 2023) in fiscal year 2023.
Merck & Co.'s annual revenue was $59.28 B in fiscal year 2022.
Merck & Co.'s quarterly revenue was $15.90 B(Q1: Mar 2022), $14.59 B(Q2: Jun 2022), $14.96 B(Q3: Sep 2022), $13.83 B(Q4: Dec 2022) in fiscal year 2022.
Merck & Co.'s annual revenue was $48.70 B in fiscal year 2021.
Merck & Co.'s quarterly revenue was $10.63 B(Q1: Mar 2021), $11.40 B(Q2: Jun 2021), $13.15 B(Q3: Sep 2021), $13.52 B(Q4: Dec 2021) in fiscal year 2021.
Merck & Co.'s annual revenue was $41.52 B in fiscal year 2020.
Merck & Co.'s quarterly revenue was $12.06 B(Q1: Mar 2020), $9.35 B(Q2: Jun 2020), $10.93 B(Q3: Sep 2020), $12.52 B(Q4: Dec 2020) in fiscal year 2020.
Merck & Co.'s annual revenue was $39.12 B in fiscal year 2019.
Merck & Co.'s quarterly revenue was $10.82 B(Q1: Mar 2019), $11.76 B(Q2: Jun 2019), $12.40 B(Q3: Sep 2019), $11.87 B(Q4: Dec 2019) in fiscal year 2019.
Merck & Co.'s annual revenue was $42.29 B in fiscal year 2018.
Merck & Co.'s quarterly revenue was $10.04 B(Q1: Mar 2018), $10.47 B(Q2: Jun 2018), $10.79 B(Q3: Sep 2018), $11.00 B(Q4: Dec 2018) in fiscal year 2018.
Merck & Co.'s annual revenue was $40.12 B in fiscal year 2017.
Merck & Co.'s quarterly revenue was $9.43 B(Q1: Mar 2017), $9.93 B(Q2: Jun 2017), $10.33 B(Q3: Sep 2017), $10.43 B(Q4: Dec 2017) in fiscal year 2017.
Merck & Co.'s annual revenue was $39.81 B in fiscal year 2016.
Merck & Co.'s quarterly revenue was $9.31 B(Q1: Mar 2016), $9.84 B(Q2: Jun 2016), $10.54 B(Q3: Sep 2016), $10.12 B(Q4: Dec 2016) in fiscal year 2016.
| 2015 | 0 |
|---|---|
| 2016 | +0.78 |
| 2017 | +0.79 |
| 2018 | +5.41 |
| 2019 | -7.50 |
| 2020 | +6.13 |
| 2021 | +17.31 |
| 2022 | +21.72 |
| 2023 | +1.40 |
| 2024 | +6.74 |
| 2025 | +1.31 |
| Q1: Mar 16 | -1.20 |
|---|---|
| Q2: Jun 16 | 0.60 |
| Q3: Sep 16 | 4.60 |
| Q4: Dec 16 | -0.98 |
| Q1: Mar 17 | 1.31 |
| Q2: Jun 17 | 0.87 |
| Q3: Sep 17 | -2.00 |
| Q4: Dec 17 | 3.14 |
| Q1: Mar 18 | 6.39 |
| Q2: Jun 18 | 5.39 |
| Q3: Sep 18 | 4.54 |
| Q4: Dec 18 | 5.42 |
| Q1: Mar 19 | 7.76 |
| Q2: Jun 19 | 12.37 |
| Q3: Sep 19 | 14.85 |
| Q4: Dec 19 | 7.91 |
| Q1: Mar 20 | 11.47 |
| Q2: Jun 20 | -20.47 |
| Q3: Sep 20 | -11.84 |
| Q4: Dec 20 | 5.45 |
| Q1: Mar 21 | -11.86 |
| Q2: Jun 21 | 21.91 |
| Q3: Sep 21 | 20.36 |
| Q4: Dec 21 | 8.04 |
| Q1: Mar 22 | 49.63 |
| Q2: Jun 22 | 27.99 |
| Q3: Sep 22 | 13.72 |
| Q4: Dec 22 | 2.29 |
| Q1: Mar 23 | -8.89 |
| Q2: Jun 23 | 3.03 |
| Q3: Sep 23 | 6.70 |
| Q4: Dec 23 | 5.78 |
| Q1: Mar 24 | 8.89 |
| Q2: Jun 24 | 7.16 |
| Q3: Sep 24 | 4.35 |
| Q4: Dec 24 | 6.79 |
| Q1: Mar 25 | -1.56 |
| Q2: Jun 25 | -1.90 |
| Q3: Sep 25 | 3.72 |
| Q4: Dec 25 | 4.97 |
| Q1: Mar 26 | 4.87 |
| Q2: Jun 26 | 5.07 |
Merck & Co.โs annual revenue increased +1.31% during fiscal year 2025 compared to 2024. It represents a growth of $843.00 M from $64.17 B (in 2024) to $65.01 B (in 2025).
Merck & Co.โs annual revenue increased +6.74% during fiscal year 2024 compared to 2023. It represents a growth of $4.05 B from $60.12 B (in 2023) to $64.17 B (in 2024).
Merck & Co.โs annual revenue increased +1.40% during fiscal year 2023 compared to 2022. It represents a growth of $832.00 M from $59.28 B (in 2022) to $60.12 B (in 2023).
Merck & Co.โs annual revenue increased +21.72% during fiscal year 2022 compared to 2021. It represents a growth of $10.58 B from $48.70 B (in 2021) to $59.28 B (in 2022).
Merck & Co.โs annual revenue increased +17.31% during fiscal year 2021 compared to 2020. It represents a growth of $7.19 B from $41.52 B (in 2020) to $48.70 B (in 2021).
Merck & Co.โs annual revenue increased +6.13% during fiscal year 2020 compared to 2019. It represents a growth of $2.40 B from $39.12 B (in 2019) to $41.52 B (in 2020).
Merck & Co.โs annual revenue decreased -7.50% during fiscal year 2019 compared to 2018. It represents a decline of $3.17 B from $42.29 B (in 2018) to $39.12 B (in 2019).
Merck & Co.โs annual revenue increased +5.41% during fiscal year 2018 compared to 2017. It represents a growth of $2.17 B from $40.12 B (in 2017) to $42.29 B (in 2018).
Merck & Co.โs annual revenue increased +0.79% during fiscal year 2017 compared to 2016. It represents a growth of $315.00 M from $39.81 B (in 2016) to $40.12 B (in 2017).
Merck & Co.โs annual revenue increased +0.78% during fiscal year 2016 compared to 2015. It represents a growth of $309.00 M from $39.50 B (in 2015) to $39.81 B (in 2016).
| Period | Revenue | Year-over-Year Change |
|---|---|---|
|
Get instant access to data, Sign up for free 
FY 2025
|
$65.01 B |
$843.00 M
1.31%
|
| Q4: Dec 25 | $16.40 B |
$776.00 M
4.97%
|
| Q3: Sep 25 | $17.28 B |
$619.00 M
3.72%
|
| Q2: Jun 25 | $15.81 B |
-$306.00 M
1.9%
|
| Q1: Mar 25 | $15.53 B |
-$246.00 M
1.56%
|
|
Get instant access to data, Sign up for free
FY 2024
|
$64.17 B |
$4.05 B
6.74%
|
| Q4: Dec 24 | $15.62 B |
$994.00 M
6.79%
|
| Q3: Sep 24 | $16.66 B |
$695.00 M
4.35%
|
| Q2: Jun 24 | $16.11 B |
$1.08 B
7.16%
|
| Q1: Mar 24 | $15.78 B |
$1.29 B
8.89%
|
|
Get instant access to data, Sign up for free
FY 2023
|
$60.12 B |
$832.00 M
1.4%
|
| Q4: Dec 23 | $14.63 B |
$800.00 M
5.78%
|
| Q3: Sep 23 | $15.96 B |
$1.00 B
6.7%
|
| Q2: Jun 23 | $15.04 B |
$442.00 M
3.03%
|
| Q1: Mar 23 | $14.49 B |
-$1.41 B
8.89%
|
|
Get instant access to data, Sign up for free
FY 2022
|
$59.28 B |
$10.58 B
21.72%
|
| Q4: Dec 22 | $13.83 B |
$309.00 M
2.29%
|
| Q3: Sep 22 | $14.96 B |
$1.81 B
13.72%
|
| Q2: Jun 22 | $14.59 B |
$3.19 B
27.99%
|
| Q1: Mar 22 | $15.90 B |
$5.27 B
49.63%
|
|
Get instant access to data, Sign up for free
FY 2021
|
$48.70 B |
$7.19 B
17.31%
|
| Q4: Dec 21 | $13.52 B |
$1.01 B
8.04%
|
| Q3: Sep 21 | $13.15 B |
$2.23 B
20.36%
|
| Q2: Jun 21 | $11.40 B |
$2.05 B
21.91%
|
| Q1: Mar 21 | $10.63 B |
-$1.43 B
11.86%
|
|
Get instant access to data, Sign up for free
FY 2020
|
$41.52 B |
$2.40 B
6.13%
|
| Q4: Dec 20 | $12.52 B |
$647.00 M
5.45%
|
| Q3: Sep 20 | $10.93 B |
-$1.47 B
11.84%
|
| Q2: Jun 20 | $9.35 B |
-$2.41 B
20.47%
|
| Q1: Mar 20 | $12.06 B |
$1.24 B
11.47%
|
|
Get instant access to data, Sign up for free
FY 2019
|
$39.12 B |
-$3.17 B
7.5%
|
| Q4: Dec 19 | $11.87 B |
$870.00 M
7.91%
|
| Q3: Sep 19 | $12.40 B |
$1.60 B
14.85%
|
| Q2: Jun 19 | $11.76 B |
$1.30 B
12.37%
|
| Q1: Mar 19 | $10.82 B |
$779.00 M
7.76%
|
|
Get instant access to data, Sign up for free
FY 2018
|
$42.29 B |
$2.17 B
5.41%
|
| Q4: Dec 18 | $11.00 B |
$565.00 M
5.42%
|
| Q3: Sep 18 | $10.79 B |
$469.00 M
4.54%
|
| Q2: Jun 18 | $10.47 B |
$535.00 M
5.39%
|
| Q1: Mar 18 | $10.04 B |
$603.00 M
6.39%
|
|
Get instant access to data, Sign up for free
FY 2017
|
$40.12 B |
$315.00 M
0.79%
|
| Q4: Dec 17 | $10.43 B |
$318.00 M
3.14%
|
| Q3: Sep 17 | $10.33 B |
-$211.00 M
2%
|
| Q2: Jun 17 | $9.93 B |
$86.00 M
0.87%
|
| Q1: Mar 17 | $9.43 B |
$122.00 M
1.31%
|
|
Get instant access to data, Sign up for free
FY 2016
|
$39.81 B |
$309.00 M
0.78%
|
| Q4: Dec 16 | $10.12 B |
-$100.00 M
0.98%
|
| Q3: Sep 16 | $10.54 B |
$463.00 M
4.6%
|
| Q2: Jun 16 | $9.84 B |
$59.00 M
0.6%
|
| Q1: Mar 16 | $9.31 B |
-$113.00 M
1.2%
|
Agilent Technologies Revenue
Eli Lilly and Company Revenue
Stryker Corporation Revenue
Johnson & Johnson Revenue
AbbVie Revenue
Thermo Fisher Scientific Revenue
Abbott Laboratories Revenue
Danaher Corporation Revenue
Amgen Revenue
